Profile data is unavailable for this security.
About the company
SEIKAGAKU CORPORATION is principally engaged in the research, development, purchase, manufacture and sale of pharmaceutical products and limulus amebocyte lysate (LAL). The Company operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.
- Revenue in JPY (TTM)38.36bn
- Net income in JPY2.02bn
- Incorporated1947
- Employees988.00
- LocationSeikagaku Corp10F, Marunouchi Center Bldg1-6-1, MarunouchiCHIYODA-KU 100-0005JapanJPN
- Phone+81 352208950
- Fax+81 352208951
- Websitehttps://www.seikagaku.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adimmune Corp | 7.86bn | -2.89bn | 45.56bn | 564.00 | -- | 1.87 | -- | 5.80 | -1.44 | -1.44 | 3.93 | 11.92 | 0.1848 | 1.25 | 4.04 | -- | -8.27 | 0.6867 | -10.19 | 0.7739 | 27.82 | 30.11 | -44.75 | 3.04 | 1.99 | -24.75 | 0.3284 | 32.80 | -20.72 | 16.77 | -319.91 | -- | 38.05 | -- |
| Cuorips Inc | 19.22m | -770.78m | 45.60bn | 59.00 | -- | 8.15 | -- | 2,372.14 | -102.64 | -102.64 | 2.59 | 696.57 | 0.0032 | 0.83 | 11.65 | 325,813.60 | -12.67 | -- | -13.03 | -- | 56.90 | -- | -4,011.54 | -- | 36.15 | -14.12 | 0.00 | -- | -39.65 | -- | -39.84 | -- | -- | -- |
| Shanghai Serum Bio-Technology Co Ltd | 4.21bn | 1.09bn | 46.33bn | 321.00 | 42.61 | 1.95 | -- | 11.00 | 0.4706 | 0.4706 | 1.82 | 10.30 | 0.1735 | 1.14 | 3.91 | 614,647.90 | 4.48 | 10.43 | 4.56 | 10.84 | 76.60 | 80.54 | 25.81 | 32.57 | 42.72 | -- | 0.004 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
| Panacea Biotec Ltd | 10.06bn | -271.82m | 46.37bn | 1.15k | -- | 3.04 | 127.01 | 4.61 | -2.46 | -2.46 | 90.20 | 135.98 | 0.4374 | 1.10 | 7.87 | 4,799,546.00 | -1.22 | 10.26 | -1.65 | 16.53 | 63.28 | 50.27 | -2.79 | 24.87 | 1.03 | -13.78 | 0.0254 | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Seikagaku Corp | 38.36bn | 2.02bn | 46.42bn | 988.00 | 22.12 | 0.5923 | 11.98 | 1.21 | 36.93 | 36.93 | 703.07 | 1,379.48 | 0.4679 | 1.93 | 4.88 | 38,827,940.00 | 2.46 | 0.4261 | 2.66 | 0.4678 | 47.98 | 54.18 | 5.25 | 0.9814 | 4.53 | -- | 0.0051 | 465.78 | 8.24 | 4.99 | -2.24 | -0.5224 | 30.28 | 0.00 |
| Alliance Pharma plc | 35.63bn | -6.53bn | 46.80bn | 290.00 | -- | 1.08 | -- | 1.31 | -0.0622 | -0.0622 | 0.3378 | 0.4124 | 0.4016 | 2.72 | 4.67 | 627,215.80 | -7.36 | -0.5982 | -8.08 | -0.6566 | 59.42 | 62.45 | -18.34 | -1.80 | 2.06 | 4.45 | 0.3218 | -- | 7.92 | 8.86 | -56.24 | -- | -25.01 | -- |
| Golden Throat Holdings Group Co Ltd | 21.46bn | 5.59bn | 46.83bn | 860.00 | 8.37 | 1.71 | 7.29 | 2.18 | 0.381 | 0.381 | 1.46 | 1.86 | 0.4994 | 3.23 | 4.07 | 1,243,848.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
| PharmaSGP Holding SE | 17.77bn | 2.95bn | 47.01bn | 93.00 | 15.94 | 8.90 | 10.52 | 2.65 | 1.52 | 1.52 | 9.15 | 2.72 | 0.8223 | 1.04 | 8.57 | 1,233,225.00 | 13.64 | 13.70 | 18.34 | 19.98 | 90.91 | 90.20 | 16.59 | 17.56 | 1.54 | 14.98 | 0.6823 | -- | 17.80 | 10.78 | 37.17 | 2.16 | 25.88 | -- |
Data as of Nov 22 2024. Currency figures normalised to Seikagaku Corp's reporting currency: Japanese Yen JPY
15.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Asset Management (Japan) Ltd.as of 13 Sep 2024 | 3.84m | 6.75% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 1.28m | 2.25% |
| Nomura Asset Management Co., Ltd.as of 07 Nov 2024 | 1.17m | 2.06% |
| Nikko Asset Management Co., Ltd.as of 08 Nov 2024 | 621.50k | 1.09% |
| Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 526.20k | 0.93% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 427.31k | 0.75% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 22 Jul 2024 | 321.10k | 0.57% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 155.40k | 0.27% |
| Bessemer Investment Management LLCas of 31 Jul 2024 | 125.20k | 0.22% |
| Invesco Hong Kong Ltd.as of 13 Sep 2024 | 99.90k | 0.18% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
